In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

AveXis nets $432mm in FOPO to fund neuromuscular disease programs

Executive Summary

AveXis Inc. (gene therapies for rare musculoskeletal and neurological genetic diseases) netted $432mm in a public offering of 4.5mm shares (including the overallotment) at $102. Concurrent with the financing, the company announced an expanded development program for lead compound AVXS101 in spinal muscular atrophy (SMA) Type 1 (for which it has orphan drug, breakthrough therapy, and fast track designations), including testing the Phase I compound in new SMA patient populations such as Type 2 and Type 3 (grouped based on disease onset and severity). AveXis will use the proceeds to fund research, manufacturing, development, licensing, and pre-commercialization activities for AVXS101 in SMA as well as clinical activities for other programs in Rett syndrome and ALS.
Deal Industry
  • Pharmaceuticals
  • Pharmaceuticals
    • Drug Delivery
      • Macromolecule
  • Biotechnology
    • Gene Therapy, Cell Therapy
    • Large Molecule
Deal Status
  • Final
Deal Type
  • Financing
    • FOPO

Related Companies